partnering

Here is a great article on partnering trends which may be of interest to holders .
[Importantly, mid-stage out-licensing deals got a big boost in 2003. These alliances, signed when the product candidate is in preclinical development or Phase I clinical trials, have become increasingly attractive to partners wishing to identify an appealing product opportunity – and they valued these deals at a premium (an average of nearly $100 million per deal, more than twice as much as the average value for mid-stage deals in 2002). That year, the late-stage deals, signed when the drug candidate is more advanced – from Phase II trials forward, including approval – were all the rage, commanding average valuations of about $121 million. ]
For the full article
http://www.signalsmag.com/signalsmag.nsf/0/C0D67BEC3F48A27F88256E3800133859